secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001390478-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023
-------------------------------------------------------------------------------

- Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.
- Phase 3 REGAL (GPS) interim analysis expected late 2023/early 2024; IDMC meeting in Q3 2023.
- Phase 2a SLS009 in AML dosed; topline data expected Q4 2023; Phase 1 safety completed.
- Expects $13M milestone payments from 3D Medicines by end of Q3 2023.
- R&D expenses $5.9M (up from $5.5M) driven by GPS and SLS009 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/0001390478-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/sls-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001390478-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer